AbbVie Inc.
Company Stats
- Market Cap
- $462.3B
- as of Sep 30, 2026
- Enterprise Value
- $522.0B
- Shares Outstanding
- 1.8B
- Free Float
- 99.9%
Income Statement
- Revenue
- $61.2B
- Operating Income
- $15.1B
- Net Income
- $4.2B
- EBITDA
- $15.8B
- Revenue Growth, 3Y
- 1.8%
- FCF Margin, 3Y Avg
- 33.8%
- FCF Margin, Worst Year
- 29.1%
Cash Flow
- Free Cash Flow
- $17.8B
- FCF Yield
- 3.9%
- Owner FCF Yield
- 3.6%
Balance Sheet
- Cash & Equivalents
- $5.2B
- Total Debt
- $65.0B
- Net Debt
- $59.8B
- Net Debt / EBITDA
- 3.77x
- EV / EBITDA
- 32.96x
- Net Debt / EBIT
- 3.96x
Returns & Capital
- Dividends Paid
- $11.7B
- Dividend Yield
- 2.5%
- Dividend Payout, 3Y Avg
- 250.1%
- Share Repurchases
- $980.0M
- Buyback Yield, 3Y Avg
- 0.3%
- SBC, 3Y Avg
- $871.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $61.2B | $17.8B | 29.1% |
| FY2024 | $56.3B | $17.8B | 31.7% |
| FY2023 | $54.3B | $22.1B | 40.6% |
| FY2022 | $58.1B | $24.2B | 41.8% |
| FY2021 | $56.2B | $22.0B | 39.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 12, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
November 4, 2026
Peer Earnings Note
Bristol Myers and AbbVie Take Different Paths to Fund Growth
October 24, 2026
Companies
AbbVie wins FDA approval for at-home Skyrizi initiation
October 10, 2026
Weekly Earnings
Delta and PepsiCo lower earnings outlooks as revenue rises
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
AbbVie’s Rinvoq offers oral treatment for a defined colitis population
September 23, 2026
Drug Pipeline
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
September 23, 2026
Drug Pipeline
AbbVie’s Skyrizi extends its IL-23 role into ulcerative colitis
September 4, 2026
Deals
AbbVie Completes $10.9 Billion Cash Purchase of Apogee
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 22, 2026
Deals
AbbVie to Buy Apogee Therapeutics in $10.9 Billion All-Cash Deal
Bristol Myers and AbbVie Take Different Paths to Fund Growth
October 24, 2026
Companies
AbbVie wins FDA approval for at-home Skyrizi initiation
October 10, 2026
Weekly Earnings
Delta and PepsiCo lower earnings outlooks as revenue rises
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
AbbVie’s Rinvoq offers oral treatment for a defined colitis population
September 23, 2026
Drug Pipeline
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
September 23, 2026
Drug Pipeline
AbbVie’s Skyrizi extends its IL-23 role into ulcerative colitis
September 4, 2026
Deals
AbbVie Completes $10.9 Billion Cash Purchase of Apogee
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 22, 2026
Deals
AbbVie to Buy Apogee Therapeutics in $10.9 Billion All-Cash Deal